Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Entity

Kowa (company)

Tracked across 3 events · 19 articles · First seen Apr 23, 2026 · Last active Sep 02, 2026

Sentiment
43
Attention
4
Events
3
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 60
Business
Impact: Kowa (company) is NicOx's exclusive U.S. partner for NCX 470 and is expected to submit the New Drug Application for the drug in the U.S. in summer 2026. Kowa (company) bears the commercialization costs for its licensed territories.
Jun 18, 2026 · 7 articles
2 30
Business
Impact: Kowa (company) is NicOx's exclusive U.S. partner for NCX 470 and anticipates a commercial launch in H2 2027 subject to approval. The expected approval milestone and royalties are key to NicOx's extended runway.
Sep 02, 2026 · 6 articles
4 40
Regulatory
Impact: Kowa (company) is NicOx's partner for the rest of the world and recently submitted the U.S. NDA. Its regulatory progress is aligned with NicOx's commercialization strategy.
Aug 10, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Kowa (company) live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.